“With the brepocitinib CS program now moving into Phase 3 alongside the dermatomyositis and non-infectious uveitis programs, Priovant continues to advance our goal of developing brepocitinib as a ...

The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...

WASHINGTON, DC – When billionaires are in the spotlight for their oversized influence in Washington, especially in the Trump administration, comes this news: Vivek Ramaswamy’s wealth has soared even ...

Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced the appointment of Maykin Ho, Ph.D., to its board of directors, and the promotions of Nathan ...

Greenlight Capital's David Einhorn has been vocal about his concerns around artificial intelligence driving overvaluation in ...

Pulmovant, a Roivant Sciences subsidiary, has completed enrollment in the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease. The PHocus study is ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating.

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Bates has welcomed a large group of new faculty this year. Seventeen tenured or tenure-track professors joined the college during the 2025-2026 academic year. Bates News has been introducing them in ...

Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.